Crystagen
EDP Tripeptide | Thymus Immune Bioregulator
Availability
Crystagen is currently available through specialized research suppliers
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
Mechanism of Action
Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).
Key Benefits
- Normalizes immune function in 82% of patients
- Stimulates normal lymphocyte proliferation
- Inhibits tumor cell growth (antitumor activity)
- Doubles HSP gene expression (stress resistance)
- Reduces respiratory viral infections
- Activates B-cell immune system
- Normalizes IL-6 expression
- Effective after radiation/chemotherapy
EDPGlutamic Acid
Position 1
Aspartic Acid
Position 2
Proline
Position 3
Immune Support
- Immune Dysfunction
Normalizes immunogram in elderly patients with impaired immunity.
- Post-Infection Recovery
Restores immune function after infectious diseases.
- Radiation/Chemo Recovery
Helps normalize immunity after radiation and chemotherapy exposure.
Stress Resistance
- Athletic Immune Support
Increases stress resistance and reduces respiratory infections in athletes.
- HSP Expression
Doubles expression of heat-shock protein gene HSPA1A.
Anti-Tumor
- Tumor Cell Inhibition
Inhibits proliferation of K-562 human erythromyelosis tumor cells.
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles, often repeated 2-3 times per year.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | Oral capsules |
| Maintenance | 10 mg | 2-3 cycles yearly | Oral capsules |
| Athletic support | 10-20 mg | Daily during training cycles | Oral capsules |
Both have immunoprotecting properties; different mechanisms complement each other.
Crystagen (EDP) is derived from thymalin; complementary immune effects.
Often combined in comprehensive anti-aging Khavinson protocols.
Related immune peptides; can be used together.
Immune activation and gene expression modulation begins
Effects persist due to epigenetic changes
Measurable immune function improvements
Cumulative benefits with periodic cycles
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual immune symptoms
Contraindications
- Active autoimmune flares (consult physician)
- Known hypersensitivity
- Pregnancy or breastfeeding
Good Signs
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Warning Signs
- Unknown source or purity
Bad Signs
- Discoloration
- Unusual odor
- Damaged packaging
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.